Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. MU
2. SPCX
3. APTX:CN
4. SPY
5. IQMX
6. EROC
7. MSTR
8. MSFT
9. SEER
10. NVDA

Go back to Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis

Mesoblast (MESO) Reports Q2 Loss of $0.06

February 16, 2016 4:59 PM EST

Mesoblast (NASDAQ: MESO) reported Q2 EPS of ($0.06), versus ($0.09) reported last year. Revenue for the quarter came in at $4 million, versus $4.4 million reported last year.

For earnings history and earnings-related data on Mesoblast (MESO) click here.

... More